Gilead Sciences Set to Acquire CAR-T Developer Kite Pharma
August 28th 2017Kite's most advanced therapy candidate, axicabtagene ciloleucel (axi-cel), is a CAR T therapy currently under priority review by the US FDA, and is expected to be a treatment option for refractory aggressive non-Hodgkin lymphoma,
Read More